Literature DB >> 11117640

Genetic diversity among strains of Moraxella catarrhalis cultured from the nasopharynx of young and healthy Brazilian, Angolan and Dutch children.

B Wolf1, M Kools-Sijmons, C Verduin, L C Rey, A Gama, J Roord, J Verhoef, A van Belkum.   

Abstract

The present study describes the carriage patterns and genetic variability of Moraxella catarrhalis strains isolated from children living in different countries. Moraxella catarrhalis is genetically heterogeneous, but little is known about its geographic distribution and phenotypic and genetic diversity in warm-climate countries. A collection of 99 isolates from 30 Brazilian, 19 Angolan and 50 Dutch healthy children, all less than 5 years of age, was investigated for phenotypic and genotypic relatedness. The isolates from the three countries were similar where biochemical reactivity was concerned: 89 strains were beta-lactamase-producing and 87 were complement-resistant as determined by phenotype. There was no geographical difference in the prevalence of beta-lactamase-producing isolates, but the carriage rate of complement-resistant strains was significantly higher in Dutch than in Angolan children (P=0.004). Complement resistance of 66 randomly selected strains was genetically confirmed in a Southern hybridization assay by a novel DNA probe that is specific for complement-resistant strains and that demonstrated a sensitivity of 97% and a specificity of 100%. PCR amplification based on the probe sequence had a sensitivity of 98% and a specificity of 57% when compared to the outcome of a conventional culture spot test. PCR restriction fragment length polymorphism analysis of the MU 46 locus and pulsed-field gel electrophoresis of SpeI DNA macrorestriction fragments revealed genetic heterogeneity of strains from within and between the three countries, and no geographical clustering could be established. In conclusion, similar phenotypic characteristics but genotypic heterogeneity was found among Moraxella catarrhalis strains colonizing children in three different continents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11117640     DOI: 10.1007/s100960000362

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  6 in total

1.  Production of BRO beta-lactamases and resistance to complement in European Moraxella catarrhalis isolates.

Authors:  Franz-Josef Schmitz; Andreas Beeck; Mirella Perdikouli; Mechthild Boos; Susanne Mayer; Sybille Scheuring; Karl Köhrer; Jan Verhoef; Ad C Fluit
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

2.  Pneumococcal vaccination does not affect the genetic diversity of Moraxella catarrhalis isolates in children.

Authors:  J P Hays; K Eadie; R Veenhoven; C M Verduin; H Verbrugh; A van Belkum
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10       Impact factor: 3.267

3.  Quantitative detection of Moraxella catarrhalis in nasopharyngeal secretions by real-time PCR.

Authors:  Oliver Greiner; Philip J R Day; Martin Altwegg; David Nadal
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

4.  The UspA2 protein of Moraxella catarrhalis is directly involved in the expression of serum resistance.

Authors:  Ahmed S Attia; Eric R Lafontaine; Jo L Latimer; Christoph Aebi; George A Syrogiannopoulos; Eric J Hansen
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

5.  The Moraxella catarrhalis immunoglobulin D-binding protein MID has conserved sequences and is regulated by a mechanism corresponding to phase variation.

Authors:  Andrea Möllenkvist; Therése Nordström; Christer Halldén; Jens Jørgen Christensen; Arne Forsgren; Kristian Riesbeck
Journal:  J Bacteriol       Date:  2003-04       Impact factor: 3.490

6.  Binding of vitronectin by the Moraxella catarrhalis UspA2 protein interferes with late stages of the complement cascade.

Authors:  Ahmed S Attia; Sanjay Ram; Peter A Rice; Eric J Hansen
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.